Literature DB >> 25333896

Polydatin supplementation ameliorates diet-induced development of insulin resistance and hepatic steatosis in rats.

Qi Zhang1, Yingying Tan1, Nan Zhang1, Fanrong Yao2.   

Abstract

The pathophysiology of non-alcoholic fatty liver disease remains to be elucidated, and the currently available treatments are not entirely effective. Polydatin, a stilbenoid compound derived from the rhizome of Polygonum cuspidatum, has previously been demonstrated to possess hepatoprotective effects. The present study aimed to determine the effects of polydatin supplementation on hepatic fat accumulation and injury in rats fed a high-fat diet. In addition, the mechanisms underlying the protective effects of polydatin were examined. Male Sprague Dawley rats were randomly divided into four groups and received one of four treatment regimes for 12 weeks: Control diet, control diet supplemented with polydatin, high-fat diet, or high-fat diet supplemented with polydatin. Polydatin was supplemented in the drinking water at a concentration of 0.3% (wt/vol). The results of the present study showed that long-term high-fat feeding resulted in fatty liver in rats, which was manifested by excessive hepatic neutral fat accumulation and elevated plasma alanine aminotransferase and aspartate aminotransferase levels. Polydatin supplementation alleviated the hepatic pathological changes, and attenuated the insulin resistance, as shown by an improved homeostasis model assessment of basal insulin resistance values and a glucose tolerance test. Polydatin supplementation also corrected abnormal leptin and adiponectin levels. Specifically, polydatin supplementation enhanced insulin sensitivity in the liver, as shown by improved insulin receptor substrate 2 expression levels and Akt phosphorylation in the rat liver, following high-fat diet feeding. The results of the present study suggest that polydatin protects rats against high-fat feeding-induced insulin resistance and hepatic steatosis. Polydatin may be an effective hepatoprotective agent and a potential candidate for the prevention of fatty liver disease and insulin resistance.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25333896     DOI: 10.3892/mmr.2014.2708

Source DB:  PubMed          Journal:  Mol Med Rep        ISSN: 1791-2997            Impact factor:   2.952


  16 in total

1.  Study of Cellular Senescence and Vitamin D Deficiency in Nonalcoholic Fatty Liver Disease and The Potential Protective Effect of Vitamin D Supplementation.

Authors:  Hasen A Al-Ghamdi; Fayza F Al Fayez; Abdulhadi I Bima; Taghreed M Khawaji; Ayman Z Elsamanoudy
Journal:  J Clin Exp Hepatol       Date:  2020-07-18

2.  Glucose-6-phosphate dehydrogenase inhibitor for treatment of severe COVID-19: Polydatin.

Authors:  Amir Hossein Doustimotlagh; Mahdieh Eftekhari
Journal:  Clin Nutr ESPEN       Date:  2021-03-15

3.  Polydatin inhibits mast cell-mediated allergic inflammation by targeting PI3K/Akt, MAPK, NF-κB and Nrf2/HO-1 pathways.

Authors:  Jing Ye; Hongmei Piao; Jingzhi Jiang; Guangyu Jin; Mingyu Zheng; Jinshi Yang; Xiang Jin; Tianyi Sun; Yun Ho Choi; Liangchang Li; Guanghai Yan
Journal:  Sci Rep       Date:  2017-09-19       Impact factor: 4.379

4.  Polydatin attenuates diet-induced nonalcoholic steatohepatitis and fibrosis in mice.

Authors:  Rui Li; Jingzhi Li; Yiji Huang; Hui Li; Sishan Yan; Jiaxin Lin; Ying Chen; Limin Wu; Bing Liu; Genshu Wang; Tian Lan
Journal:  Int J Biol Sci       Date:  2018-07-30       Impact factor: 6.580

Review 5.  Bioactive Ingredients in Chinese Herbal Medicines That Target Non-coding RNAs: Promising New Choices for Disease Treatment.

Authors:  Yan Dong; Hengwen Chen; Jialiang Gao; Yongmei Liu; Jun Li; Jie Wang
Journal:  Front Pharmacol       Date:  2019-05-21       Impact factor: 5.810

6.  The phytochemical polydatin ameliorates non-alcoholic steatohepatitis by restoring lysosomal function and autophagic flux.

Authors:  Xiaoting Chen; Hung Chan; Lin Zhang; Xiaodong Liu; Idy H T Ho; Xiang Zhang; Jeffery Ho; Wei Hu; Yuanyuan Tian; Shanglong Kou; Chee Sam Chan; Jun Yu; Sunny H Wong; Tony Gin; Matthew T V Chan; Xuegang Sun; William K K Wu
Journal:  J Cell Mol Med       Date:  2019-04-11       Impact factor: 5.310

7.  Nephroprotective Effects of Polydatin against Ischemia/Reperfusion Injury: A Role for the PI3K/Akt Signal Pathway.

Authors:  Hong-Bao Liu; Qiu-Hong Meng; Chen Huang; Jian-Bo Wang; Xiao-Wei Liu
Journal:  Oxid Med Cell Longev       Date:  2015-10-20       Impact factor: 6.543

8.  Polydatin Protects Bone Marrow Stem Cells against Oxidative Injury: Involvement of Nrf 2/ARE Pathways.

Authors:  Meihui Chen; Yu Hou; Dingkun Lin
Journal:  Stem Cells Int       Date:  2015-12-06       Impact factor: 5.443

9.  Polydatin Prevents Methylglyoxal-Induced Apoptosis through Reducing Oxidative Stress and Improving Mitochondrial Function in Human Umbilical Vein Endothelial Cells.

Authors:  Ningbo Pang; Tangting Chen; Xin Deng; Ni Chen; Rong Li; Meiping Ren; Yongjie Li; Mao Luo; Haiyan Hao; Jianbo Wu; Liqun Wang
Journal:  Oxid Med Cell Longev       Date:  2017-09-13       Impact factor: 6.543

10.  Novel natural and synthetic inhibitors of solute carriers SGLT1 and SGLT2.

Authors:  Paul Oranje; Robin Gouka; Lindsey Burggraaff; Mario Vermeer; Clément Chalet; Guus Duchateau; Pieter van der Pijl; Marian Geldof; Niels de Roo; Fenja Clauwaert; Toon Vanpaeschen; Johan Nicolaï; Tom de Bruyn; Pieter Annaert; Adriaan P IJzerman; Gerard J P van Westen
Journal:  Pharmacol Res Perspect       Date:  2019-07-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.